Novo’s booming semaglutide franchise for diabetes and obesity is the standout inclusion in this year’s list. The U.S. Department of Health and Human Services unveiled the list of 15 drugs Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback